Bringing a new medicine to people around the world requires significant resources and may involve the concerted efforts of multiple major companies and organizations. Throughout our history, global collaborations have played an important role in helping us to fully realize the productivity of our drug discovery capabilities and advance the development and commercialization of Vertex-discovered medicines. We seek to work with companies that share our sense of urgency to improve the treatment of major diseases and who share our commitment to scientific and clinical excellence.
As part of Vertex’s commitment to advance the treatment of hepatitis C around the world, we are collaborating with Janssen Pharmaceuticals, Inc., a subsidiary of Johnson and Johnson, and Mitsubishi Tanabe Pharma Corporation to develop and commercialize INCIVEK® (telaprevir). Janssen has rights to commercialize telaprevir in Europe, South America, Australia, the Middle East and certain other countries. Mitsubishi Tanabe Pharma Corporation has commercial rights for telaprevir in Japan and certain countries in Asia. Vertex retains commercial rights to INCIVEK in the U.S. and Canada.
We are also working with Alios BioPharma to advance the development of a nucleotide drug candidate for the treatment of hepatitis C. This potential medicine, which was discovered by Alios and is known as ALS-2200 (VX-135), is designed to inhibit the replication of the hepatitis C virus by acting on the NS5B polymerase. We expect to evaluate ALS-2200 (VX-135) as part of potential all-oral, interferon-free combination regimen for the treatment of hepatitis C.
Vertex initiated its CF research program in 1998 as part of a collaboration with Cystic Fibrosis Foundation Therapeutics, Inc., the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation (CFF). CFF provided scientific, clinical and financial support for the discovery and early development of KALYDECO™, approved in the U.S. and Europe in 2012, and VX-809, which is being evaluated in combination with KALYDECO. Vertex continues to collaborate with CFF on the development of another potential new medicine for CF, VX-661, as well as the discovery of other CF drug candidates.